The European Commission has granted marketing authorization for Nycomed’s single dose Instanyl fentanyl nasal spray for the treatment of breakthrough pain in cancer patients. A multi-dose Instanyl product was approved by the EC in 2009 and is marketed in 50, 100, and 200 mcg dose versions. The single dose Instanyl will be available in the same dosages.
“The launch of the single-dose nasal spray will provide greater flexibility to the patient and help to manage dose titration and dose modification, as well as enabling easier tracking of patient’s use of rescue medication,” Nycomed says.
Nycomed Executive VP Guido Oelkers commented: “Development of the Instanyl single-dose nasal spray further demonstrates Nycomed’s commitment to innovation in areas of clear medical need. Over half a million cancer patients are suffering from breakthrough pain in Europe. The Instanyl single-dose nasal spray will add flexibility to the managing of their pain.”
Read the Nycomed press release.
